BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...
BioCentury | May 28, 2019
Financial News

May 28 Financial Quick Takes: Alphamab Oncology raises $60M; plus $180.5M for Panacea healthcare fund and more

...participation from new investor and entrepreneur Adrian Cheng and existing investors China Venture Capital Fund, PAG...
BioCentury | Nov 21, 2018
Finance

Alphamab's cancer cash

...through clinical testing. Investors in the round, which closed on Nov. 17, include Advantech Capital, PAG...
BioCentury | Nov 16, 2018
Financial News

Alphamab Oncology raises more than $100M series A

...series A round to accelerate development of its biologics including lead product KN035. Advantech Capital, PAG...
BioCentury | Sep 7, 2013
Politics & Policy

Hamburg forms working group of senior FDA leaders

...and user fee programs. According to an internal memo from Hamburg, the Program Alignment Group (PAG...
Items per page:
1 - 5 of 5
BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...
BioCentury | May 28, 2019
Financial News

May 28 Financial Quick Takes: Alphamab Oncology raises $60M; plus $180.5M for Panacea healthcare fund and more

...participation from new investor and entrepreneur Adrian Cheng and existing investors China Venture Capital Fund, PAG...
BioCentury | Nov 21, 2018
Finance

Alphamab's cancer cash

...through clinical testing. Investors in the round, which closed on Nov. 17, include Advantech Capital, PAG...
BioCentury | Nov 16, 2018
Financial News

Alphamab Oncology raises more than $100M series A

...series A round to accelerate development of its biologics including lead product KN035. Advantech Capital, PAG...
BioCentury | Sep 7, 2013
Politics & Policy

Hamburg forms working group of senior FDA leaders

...and user fee programs. According to an internal memo from Hamburg, the Program Alignment Group (PAG...
Items per page:
1 - 5 of 5